Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

9 Jan 2020 07:00

RNS Number : 1997Z
InnovaDerma PLC
09 January 2020
 

LEI: 213800WRAP6W8VDL6B38

InnovaDerma PLC

("InnovaDerma" or the "Company")

Trading Statement

InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life sciences products, provides a trading update for the six months ended 31 December 2019.

The Company generated revenues of £5.0m, up c.28% compared to the same period last year (H1 2019: £3.9m). The increase in revenue was driven predominantly by Skinny Tan and its performance on the Company's DTC platform and in the UK retail channel. The former has continued to benefit from a revised digital engagement strategy and investment in all three key geographical markets: UK, US and Australia. Product innovation remains key to the business and the first six months included the launch of the limited-edition Choc range in Superdrug, which resulted in exceptional demand and the continued success of Wonder Serum in Boots has provided a strong platform for the season ahead. These initiatives have alleviated the effects of a softer UK high street retail environment and shelf space rationalisation, typical of seasonal products such as Skinny Tan.

The UK DTC channel accounted for 56% of total revenue (H1 2019: 59%). Skinny Tan DTC revenue was supported by Black Friday and Christmas promotions, up c.27% compared to the same period last year. UK retail revenue was almost double that of H1 2019, driven by the Skinny Tan rollout into Boots' stores, an opening order from Tesco, and continued support from Superdrug. Pleasingly, our core brand also made excellent progress in Australia and the US DTC markets, with the introduction of new products. Whilst these two territories remain a small proportion of our overall revenue, growth was robust.

Roots revenues were lower than expected due to competitive shelf positioning, however, new products, particularly Platinum Colour Protect, performed well. Charles + Lee continued to build momentum with Australian retailers and almost doubled revenues compared to last year.

Life Sciences' revenue increased by 71% on the previous year as a result of DTC sales driven by online 'influencers', predominantly in the US.

As in previous years, the Company expects revenue and profit growth to be strongly weighted to H2 FY2020, reflecting the peak tanning season. Skinny Tan remains well positioned to perform well in the UK despite a challenging outlook for the UK retail market. Charles & Lee is growing in popularity, and we look forward to expanding its geographical spread. Roots will receive extra marketing and product development focus to expand its customer base and product offering in 2020.

The momentum of the first half coupled with our forthcoming new category launch give us much confidence for the full year. The balance sheet remains healthy and with an increased retail footprint coupled with continued focus on our DTC channels in core regions, the Company expects to generate strong revenue and profit growth in the second half of the year.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Further enquiries

InnovaDerma

Joe Bayer

Kieran Callan c/o TB Cardew

www.innovaderma.com

 

 

+61 (0)3 9863 8030

+44 (0)20 7930 0777

finnCap Ltd

Geoff Nash/ Kate Bannatyne

Alice Lane/Manasa Patil - Corporate Broking

 

 

+44 (0)207 220 0500

www.finncap.com

TB Cardew

Shan Shan Willenbrock/Tom Allison

Olivia Rosser

 

+ 44 (0)20 7930 0777

innovaDerma@tbcardew.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKFBNPBKDCDK
Date   Source Headline
5th May 20172:05 pmRNSSecond Price Monitoring Extn
5th May 20172:00 pmRNSPrice Monitoring Extension
3rd May 20172:06 pmRNSSecond Price Monitoring Extn
3rd May 20172:00 pmRNSPrice Monitoring Extension
3rd May 20177:15 amRNSCompany update and Directorate Change
2nd May 20177:00 amRNSAcquisition
28th Apr 20178:05 amRNSBroker Warrants
11th Apr 20177:00 amRNSAllotment of Shares
3rd Apr 20177:00 amRNSTrading update
3rd Mar 20174:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20174:35 pmRNSPrice Monitoring Extension
3rd Mar 20172:05 pmRNSSecond Price Monitoring Extn
3rd Mar 20172:00 pmRNSPrice Monitoring Extension
2nd Mar 201711:18 amRNSExercise of Share Options
1st Mar 20177:00 amRNSCompletion of Acquisitions
27th Feb 20177:00 amRNSAcquisition of Stevie K and Charles + Lee Brands
9th Feb 20177:00 amRNSHalf-year Report
30th Jan 20177:00 amRNSDirectorate Change
27th Jan 201711:17 amRNSNotice of Results
25th Jan 20178:00 amRNSHeads of Agreement with PROS Korea
16th Jan 20177:00 amRNSTrading Statement
10th Jan 20177:00 amRNSDirectorate Change
9th Jan 20179:06 amRNSSecond Price Monitoring Extn
9th Jan 20179:00 amRNSPrice Monitoring Extension
19th Dec 20163:18 pmRNSHolding(s) in Company
15th Dec 201610:08 amRNSResult of AGM
14th Dec 20169:45 amRNSPlacing
8th Dec 20167:00 amRNSCompletion of Placing
6th Dec 20167:30 amRNSGeneral Manager appointed for the UK and Europe
25th Nov 20167:00 amRNSPlacing and Fundraising
17th Nov 20164:34 pmRNSNotice of AGM & Posting of Annual Report
16th Nov 20161:54 pmRNSBroker Warrants
14th Nov 20167:00 amRNSPublication of Supplementary Prospectus
11th Nov 201611:23 amRNSDirector/PDMR Shareholding
31st Oct 201610:25 amRNSFinal Results
31st Oct 20167:00 amRNSInnovaDerma enters US market
24th Oct 20167:00 amRNSOperational update & presentation published online
21st Oct 20162:15 pmRNSIssue of Equity
20th Oct 201611:05 amRNSSecond Price Monitoring Extn
20th Oct 201611:00 amRNSPrice Monitoring Extension
10th Oct 20167:00 amRNSTrading Statement
9th Sep 201612:38 pmRNSVoluntary Suspension of Trading on Marche Libre
7th Sep 20167:00 amRNSAdmission to the Official List

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.